

COVID-19 IMMUNITY

Research Roundup

Your weekly review on COVID-related research



International Research Review

Several studies suggest single dose of vaccine provides strong protection for people who have recovered from COVID-19

Several studies have shown that a single dose of the coronavirus mRNA vaccine can induce a strong immune response in people with previous infection – strong enough to possibly protect them from future disease. These reports, including two new papers published in The Lancet at the end of February, and their implications in terms of vaccine deployment policies, are summarized here.

Read Summary

The never-ending battle for many COVID-19 patients

A negative test may not necessarily mean the end of a case of COVID-19. Many individuals continue to suffer from debilitating symptoms such as fatigue, cough, and joint and chest pain for as long as six months. A summary of the latest research on long COVID (also known as chronic COVID syndrome or long-haul COVID) is found here.

Read Summary

New SARS-CoV-2 VOC in New York City, on-going challenges & advancements

The global emergence of multiple variants of concern (VOCs) has led to increasing efforts to sequence viruses in multiple localized communities around the world. To date, a number of these variants have been shown to potentially render antibody-based therapies ineffective at controlling the virus. Now, a new B.1.526 variant has emerged in New York City, rapidly becoming the primary variant in that region. While this variant may limit the usefulness of antibody-based therapies, new teams are working on developing original antibody clones that will be better poised to meet these emerging VOCs.

Read Summary



Spotlight on CITF-funded Research

Passport to normal: CITF researcher Kumanan Wilson comments on the future of immunity passports

With vaccine coverage on the horizon, many people are starting to think about how to document immunization. In this article, CITF-funded researcher Dr. Kumanan Wilson from the University of Ottawa and the Bruyère Research Institute and colleague Colleen Flood from the University of Ottawa, discuss how SARS-CoV-2 immunization passports could work, the infrastructure required to operationalize them, and potential barriers and limitations to their use.

COVID-19 should be considered in all hospitalized children

One of the CITF's scientific advisors collaborated in a study that followed hospitalized children with a diagnosis of COVID-19. The study, carried out in Canada, Iran, and Costa Rica, found that approximately half of the children diagnosed with a SARS-CoV-2 infection during hospitalization were originally admitted with another diagnosis.

Read More

Pan-Canadian studies investigate why COVID-19 has been so devastating to long-term care facility residents and staff

Long-term care facilities have been disproportionately burdened by COVID-19, accounting for about 60% of COVID-19 deaths nationwide, 70% if retirement homes are included. Two more studies have begun investigating various aspects of immunity and people's response to vaccines within longterm care facilities in Ontario, Quebec and British Columbia.

Read More

Study underway in Nova Scotia long-term care facilities to determine health factors related to severe COVID-19 outcomes and vaccine effectiveness

Another study, this one in Nova Scotia, aims to determine which health factors cause long-term care residents to experience severe COVID-19 outcomes, including death. The study is also investigating vaccine effectiveness in this elderly population over the next year. It will be carried out by a team of experts in frailty research, immunology, virology and clinical infectious disease.

Three Canadian studies will help determine how many teachers may have had COVID-19

Three research projects, out of Ontario, Quebec and British Columbia, will estimate how many teachers and school personnel have been infected with SARS-CoV-2. The studies will also evaluate the effects of the pandemic on teachers' mental health.

Read More



Share your Research

Have a publication we should review or know about? Please share with us at research@covid19immunitytaskforce.ca